NASDAQ
76.76USD
-4.61 (-5.67%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
9.6B
P/E
—
EPS
—
Beta
0.38
52W range
32.89-88.31
Day range
75.87–81.37
Open
81.23
Prev close
81.37
Volume
3.6M
Avg volume
2.6M
Dividend
0.00
IPO
2004-04-26
https://www.zacks.com/stock/news/2956324/are-medical-stocks-lagging-concentra-group-holdings-parent-inc-con-this-year?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_1-2956324 · 7/20/2026+0.80
https://www.zacks.com/stock/news/2953961/wall-street-analysts-think-cytokinetics-cytk-could-surge-30-54-read-this-before-placing-a-bet?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|consensus_price_target-2953961 · 7/15/2026+0.80
https://www.fool.com/coverage/etfs/2026/07/04/which-ishares-value-etf-is-better-the-russell-2000-focused-iwn-or-ijj-targeting-mid-cap-stocks/ · 7/4/2026+0.00
https://www.globenewswire.com/news-release/2026/05/08/3291210/35409/en/Cytokinetics-Announces-Closing-of-Public-Offering-of-Common-Stock-and-Full-Exercise-of-the-Underwriters-Option-to-Purchase-Additional-Shares-for-Gross-Proceeds-of-805-Million.html · 5/8/2026
https://247wallst.com/investing/2026/05/03/3-biotech-stocks-to-watch-for-respectable-growth-beyond-ai/ · 5/3/2026+0.60
https://www.zacks.com/stock/news/2902685/can-myqorzo-drive-growth-for-cytokinetics-amid-competition · 4/17/2026+0.90
https://www.defenseworld.net/2026/03/28/cytokinetics-incorporated-nasdaqcytk-receives-average-rating-of-moderate-buy-from-brokerages.html · 3/28/2026+0.60
https://www.fool.com/coverage/filings/2026/03/21/this-usd6-5-million-healthcare-trim-comes-amid-a-71-stock-surge-and-20-revenue-growth/ · 3/21/2026+0.00
https://www.fool.com/coverage/filings/2026/03/21/this-usd8-9-million-buy-targets-a-stock-down-68-with-usd322-million-in-cash/ · 3/21/2026+0.00
https://www.globenewswire.com/news-release/2026/02/24/3244007/35409/en/Cytokinetics-Reports-Fourth-Quarter-2025-Financial-Results-and-Provides-Business-Update.html · 2/24/2026+1.00
https://www.defenseworld.net/2025/12/25/wendell-wierenga-sells-20000-shares-of-cytokinetics-nasdaqcytk-stock.html · 12/25/2025-0.20
https://www.globenewswire.com/news-release/2025/12/17/3206907/35409/en/Cytokinetics-Announces-NMPA-Approval-of-MYQORZO-aficamten-in-China-for-Patients-with-Obstructive-Hypertrophic-Cardiomyopathy.html · 12/17/2025+1.00
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
